

GENOCEA BIOSCIENCES, INC.  
Form 8-K  
May 20, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **May 20, 2015**

**GENOCEA BIOSCIENCES, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation)

**001-36289**  
(Commission File Number)

**51-0596811**  
(IRS Employer  
Identification No.)

**Cambridge Discovery Park**

**100 Acorn Park Drive, 5th Floor**  
**Cambridge, MA**  
(Address of principal executive offices)

**02140**  
(Zip Code)

(Registrant's telephone number, including area code): **(617) 876-8191**

**Not Applicable**

Edgar Filing: GENOCEA BIOSCIENCES, INC. - Form 8-K

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01. Regulation FD Disclosure.**

On May 20, 2015, Genoce Biosciences, Inc. (the Company ) issued a press release announcing top-line data from the Company s Phase 2 dose optimization trial evaluating the immunotherapy GEN-003 for the treatment of genital herpes. A copy of the press release, dated May 20, 2015, is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this Item 7.01 of this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed filed for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing.

**Item 8.01 Other Events.**

On May 20, 2015, the Company gave a presentation to certain investors regarding the top-line data from the Company s Phase 2 dose optimization trial evaluating the immunotherapy GEN-003 for the treatment of genital herpes. A copy of the presentation is attached to this Current Report on Form 8-K as Exhibit 99.2 and is incorporated herein by reference. The presentation is also available on the Company s website, [www.genoce.com](http://www.genoce.com), however the Company s website and any information contained on the website are not incorporated herein.

**Item 9.01 Financial Statements and Exhibits.**

See Exhibit Index attached hereto.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GENOCEA BIOSCIENCES, INC.**

By: /s/ Jonathan Poole  
Jonathan Poole

Chief Financial Officer

Date: May 20, 2015

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release issued by Genoceca Biosciences, Inc. on May 20, 2015
99.2	Investor Presentation dated May 20, 2015